Mesoblast (ASX:MSB; Nasdaq: MESO) announced 83% survival in ventilator-dependent COVID-19 patient with moderate/severe acute respiratory distress syndrome (ARDS) treated during the period March-April 2020 with two intravenous infusions of Mesoblast’s allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days. 75% have successfully come off ventilator support at a median of 10 days. At this time, seven have been discharged from the hospital. Patients received a variety of experimental agents prior to remestemcel-L. All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at New York City’s Mt. Sinai hospital
In contract, only 9% of ventilator-dependent COVID-19 patients at a major referral hospital network in New York City were able to come off ventilator support with treated with standard of care during in March/April 2021. Moreover, there was 88% mortality with only 12% survival among ventilator-dependent COVID-19. The poor outcomes are consistent with earlier published data from China where mortality rates of over 80% were reported in patients with COVID-19 and m...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).